參考文獻：
[1] Z Li. A new look at rheumatology in China—opportunities and challenges[J]. Nature Reviews Rheumatology, 2015, 11: 313–317.
[2] http://www.craweb.org/index.php?m=content&c=index&a=show&catid=15&id=425
[3] 王靜，趙慶杰，卓小斌，等.類風濕性關節(jié)炎的治療藥物研究進展[J], 2019, 37(6):485-490.
[4] Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate[J]. Ann Rheum Dis, 2008, 67(8):1096-1103.
[5] Weinblatt ME, Schiff M, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study[J]. Arthritis Rheum, 2013, 65(1):28-38.
[6] Schiff M, Weinblatt ME, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial[J]. Ann Rheum Dis, 2014, 73(1):86-94.
[7] Boyman O, Comte D, Spertini F. Adverse reactions to biologic agents and their medical management[J]. Nature Reviews Rheumatology, 2014, 10(10):612-627.
[8] Chen SK, Liao KP, Liu J, et al. Risk of Hospitalized Infection and Initiation of Abatacept Versus Tumor Necrosis Factor Inhibitors Among Patients With Rheumatoid Arthritis: A Propensity Score-Matched Cohort Study[J]. Arthritis Care Res (Hoboken), 2020, 72(1):9-17.
[9]Kremer JM, Dougados M, Emery P, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial[J]. Arthritis Rheum, 2005, 52(8):2263-2271.
[10]Westhovens R, Kremer JM, Emery P, et al. Long-term safety and efficacy of abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: a 7-year extended study[J]. Clin Exp Rheumatol, 2014, 32(4):553-562.
[11] Padovan M, Filippini M, Tincani A, et al. Safety of Abatacept in Rheumatoid Arthritis With Serologic Evidence of Past or Present Hepatitis B Virus Infection[J]. Arthritis Care Res (Hoboken), 2016, 68(6):738-743.
